Loading clinical trials...
Loading clinical trials...
A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung
Conditions
Interventions
Gefitinib
chemotherapy
Locations
3
South Korea
National Cancer Center, Korea
Goyang-si, Gyenggi-do, South Korea
Samsung Medical Center
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Start Date
October 1, 2005
Primary Completion Date
November 1, 2009
Completion Date
March 1, 2010
Last Updated
October 25, 2010
NCT06498635
NCT05692635
NCT05198830
NCT07190248
NCT06066138
NCT07486219
Lead Sponsor
National Cancer Center, Korea
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions